Viking Therapeutics (VKTX) Posts Q2 Loss of $1.07/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St futures rise on tech buying, Middle East peace hopes
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil falls as traders digest escalation in US-Iran strikes
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- SAP stock dips after Oracle's massive AI spending plans
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
- Wall Street indexes fall more than 1%, hit by tech, Iran war worries
- UBS sees generational semiconductor boom, highlights stock winners
Viking Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update
August 13, 2015 7:44 AM EDTPhase 2 Clinical Studies to Begin in Acute Hip Fracture and Hypercholesterolemia/Fatty Liver Disease
Completes $22.3 Million IPO
SAN DIEGO, Aug. 13, 2015 (GLOBE NEWSWIRE) -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced financial results for the second quarter of 2015 and provided an update on its clinical pipeline and other corporate developments.
Highlights From, and Subsequent to, the Three Months Ended June 30, 2015
"We made... More
